slide-1
slide-3
slide-2

WELCOME TO INNODIA

Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes

:: 05. February 2018

We are not all type 1 diabetic, but we are all ‘auto-immune’!

In an article published on Feb, 2nd 2018 in Science Immunology, INNODIA Investigators report that the self-directed autoimmune T lymphocytes that engender the islet destruction of T1D circulate in all individuals, whether diabetic or not, but reach the pancreas only in T1D patients.

read more

:: 09. November 2017

New INNODIA publication

Discovery of a new tracer targeting pancreatic beta cells for non-invasive imaging of
human pancreatic endocrine cells

read more






About innodia

INNODIA is an international consortium under the Innovative Medicines Initiative (IMI). 26 academic institutions and clinics, 4 industrial partners (EFPIA), 2 patient organizations and one SME have joined forces to significantly improve the understanding of type 1 Diabetes and to pave the way to novel therapeutic options to prevent and cure this disease.

group

33 partner

map
corner
x
For more information select one of the following partners

ACADEMIC paRtners

  • KU Leuven
  • ULB
  • MUG
  • UCPH
  • HH RH
  • INSERM
  • UH
  • UOULU
  • UTU
  • HKA
  • HMGU
  • TUD
  • UULM
  • UNISI
  • UD‘A
  • UPI
  • CHL
  • UiO
  • SUM
  • UL
  • UNIL
  • RUMC
  • LUMC
  • UCAM
  • KCL
  • MRC

EFPIA

  • Sanofi
  • Novo Nordisk
  • Eli Lilly
  • GSK

SME

  • Univercell-Biosolutions

Foundations

  • JDRF
  • THCT
imi eu efpia jdrf helmsley